Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
CureVac
About
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
- 251 - 500
Details
- Last Funding Type
- Debt Financing
- Last Funding Money Raised
- €75M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 251 - 500
- Operating Status
- Active
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 6, 2020 | Debt Financing | €75M | 1 |
European Investment Bank
|
— | Detail |
| Nov 8, 2016 | Series F | $29.50M | 1 | — | — | Detail |
| Jan 18, 2006 | Series B | €22M | 1 |
|
— | Detail |
| Jan 1, 2003 | Series A | €2.70M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
European Investment Bank
|
Yes | Debt Financing |
|
|
Yes | Series B |
|
|
— | Series F |
